Pages that link to "Q43526704"
Jump to navigation
Jump to search
The following pages link to Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea (Q43526704):
Displaying 50 items.
- Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase (Q24554376) (← links)
- Fetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathies (Q26822810) (← links)
- Methyl binding domain protein 2 mediates gamma-globin gene silencing in adult human betaYAC transgenic mice (Q28590402) (← links)
- Induction of human gamma globin gene expression by histone deacetylase inhibitors (Q33598588) (← links)
- Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study (Q33629906) (← links)
- Control of globin gene expression during development and erythroid differentiation (Q33645104) (← links)
- Pharmacological therapy (Q33953654) (← links)
- How I use hydroxyurea to treat young patients with sickle cell anemia (Q33985120) (← links)
- Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies (Q34067921) (← links)
- Correction of the sickle cell mutation in embryonic stem cells (Q34249583) (← links)
- National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008. (Q34253814) (← links)
- Hydroxyurea for sickle cell disease (Q34281892) (← links)
- Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease (Q34305589) (← links)
- Searching for the magic bullet against cancer: the butyrate saga (Q34431562) (← links)
- Beta-thalassemia intermedia and non-Hodgkin's lymphoma. (Q34981986) (← links)
- The role of hydroxyurea in the management of sickle cell disease (Q35087056) (← links)
- Exciting new treatment approaches for pathyphysiologic mechanisms of sickle cell disease (Q35098084) (← links)
- Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms (Q35098104) (← links)
- Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors (Q35809469) (← links)
- Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea (Q35811653) (← links)
- The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice (Q35859235) (← links)
- Hydroxyurea as Treatment for Sickle Cell Anemia (Q36670392) (← links)
- Sickle cell disease in Africa: burden and research priorities (Q36715984) (← links)
- Emergency department analgesia without narcotics for adults with acute sickle cell pain crisis: Case reports and review of crisis management (Q36943145) (← links)
- Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia (Q36968042) (← links)
- Effects of nitric oxide on red blood cell development and phenotype. (Q37087640) (← links)
- Utility of hydroxyurea in mast cell activation syndrome (Q37365376) (← links)
- Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease. (Q37367662) (← links)
- Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors (Q38025159) (← links)
- In VivoFootprinting UsingN-Ethyl,N-nitrosourea: Improved Resolution of the DNA–Protein Interactions in the Human γ-Globin Gene Promoter Region (Q38340646) (← links)
- Hydroxyurea (hydroxycarbamide) for sickle cell disease. (Q38692796) (← links)
- Sickle cell states and the anaesthetist (Q39513317) (← links)
- Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity (Q40245190) (← links)
- Moderate chronic pain, weight and dietary intake in African-American adult patients with sickle cell disease. (Q40360015) (← links)
- Pharmacological modification of hemoglobin F expression in sickle cell anemia: An update on hydroxyurea studies (Q40485105) (← links)
- 5'-flanking sequences mediate butyrate stimulation of embryonic globin gene expression in adult erythroid cells (Q40640479) (← links)
- Sickle cell disease pathophysiology (Q40835745) (← links)
- DNA methylation: biology and significance (Q41333669) (← links)
- Combined use of nonmyelosuppressive nitrosourea analogues with hydroxyurea in the induction of F-cell production in a human erythroleukemic cell line (Q42168704) (← links)
- Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression (Q44366699) (← links)
- Increased fetal hemoglobin levels in patients infected with human immunodeficiency virus (HIV1/2). (Q44593365) (← links)
- Inheritance of the Bantu/Benin haplotype causes less severe hemolytic and oxidative stress in sickle cell anemia patients treated with hydroxycarbamide. (Q46582473) (← links)
- Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy in β-Thalassemia Patients. (Q46633489) (← links)
- Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients (Q46636409) (← links)
- Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness (Q47113073) (← links)
- Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: What should be our goals for transfusion therapy? (Q52722005) (← links)
- Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients. (Q52884101) (← links)
- Hematologic Responses of Patients with Sickle Cell Disease to Treatment with Hydroxyurea (Q53717271) (← links)
- Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia. (Q54791501) (← links)
- KLF10gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients (Q57618969) (← links)